The CDC's Pharmacogenomic's
Studies II: The Allostatic Stress In CFS by Cort Johnson
Allostatic Load is
Increased in CFS?
Maloney, E., Gurbasani, B., Jones, J., Coelho, L., Pennachin, C and B.
Goertzel. 2006. Chronic fatigue syndrome and high allostatic load.
Pharmacogenomic 7 (3), 467-473
.
Four research groups examined the data generated
by the CDC from the two day Wichita Hospital stay. In order to determine if
signs of an altered stress response were present the Maloney-Goertzel group
measured components of allostatic load in CFS patients.
|
ALLOSTATIC LOAD
When something –
in technical terms a ‘stressor’ - threatens the healthy equilibrium
of the body (its homeostasis) the body uses hormones,
neurotransmitters and cytokines in order to maintain within a narrow
range such vital physiological parameters such as pH, temperature,
glucose levels and blood oxygen levels (McEwen 2004). Many things
can be stressors: infection, low blood sugar, low tissue
oxygenation, extremes of heat or cold, extended exercise, wounds,
pain, psychological distress, etc. are all stressors. The process of
maintaining homeostasis – the state of the body’s equilibrium - in
the face of a threat is called allostasis.
Normally, when the threat diminishes, the production of these
agents ceases and they are either metabolized or removed from the
intracellular spaces. But what happens if either the threat or the
threat response is not temporary? McEwen proposes that a chronic
activation of the stress response system will lead to an
overproduction or underproduction of the main stress mediators
mentioned above. Ultimately a chronic activation of the stress
response system can lead to tissue damage or receptor
desensitization. Indeed, increased levels of allostatic stress have
been associated with increased mortality and disease. The damage
caused by an over- or under-active allostatic stress response is
called allostatic load.
Allostatic stress is usually quantified using
hormonal and immune variables that researchers believe are
indicative of a disturbed homeostasis. In past studies these have
included cortisol, CRH, ACTH, serotonin, fibrinogen, thrombin,
anti-thrombin, IL-6, C-reactive protein, creatinine, albumin, among
others.
|
An interesting corollary of the above definition is the idea that a body
can respond effectively to a threat, say an infection, and still become ill
if the stress response is not turned back down. It may be that the
triggering agent is often superfluous - the pathogen, trauma, etc. that
triggered the aberrant stress response may be long gone before the problems
of allostatic load occur. This brings up the somewhat odd scenario of a
person responding effectively to a stressor but still getting ill
because a problem with an over-long or over-aggressive stress response.
Alternatively, where the stress response is inadequate to respond to
the threat, the damage caused comes from the stressor itself.
Allostatic Research: a short history -
The theory of allostatic stress is relatively new but studies of the effects
of allostatic load (AL) are increasing; twenty-nine papers were
published on AL in 2003, 19 of them studies. Most efforts have attempted to
characterize the contributions aging and social/psychological stress play in
increasing allostatic loads. Increased levels of psychological stress have
been shown to increase allostatic load, but social stress studies have had
mixed results. Aging has been shown to be associated with increased
allostatic load. This appears to be one of the first studies to characterize
levels of allostatic stress in a specific disease.
Increased levels of allostatic load have been associated with increased
risk of death, heart disease, cognitive problems and worsened physical
functioning in prospective studies. AL was predictive of both physical and
cognitive decline in one study.
Altering the Allostatic Stress Response -
McEwen cites four ways the stress response can be deregulated (McEwen
2000).
- repeated exposures to stressors (infection, low blood volume, low
blood glucose levels, psychological stress, etc) can result in the
stress response system being chronically turned on.
- The inability of the body to metabolize or clear stress agents such
as hormones or neurotransmitters from its system can lead to the stress
response being chronically turned on.
- A overly sensitive stress response system that on a hair trigger can
be chronically turned on.
- A stress response that is under-responsive will leave the
body vulnerable to the effects of stressors.
Why focus on the stress response in CFS? One reason is surely the low
levels of the main adrenal stress hormone cortisol commonly found in CFS.
Another may be the different triggers for the disease. Prospective studies
have identified three pathogenic triggers (EBV, Coxiella burnetii,
Ross-River Virus). Other studies have indicated increased psychological
stress can predispose one to CFS and anecdotal reports indicate that toxin
exposure, anorexia nervosa and pain (physical trauma) may as well. (Of
course many CFS patients cannot point to a physically or psychologically
troubling factor that preceded their CFS). Given the disparate nature of
these triggers it is not illogical to posit that something as fundamental as
the stress response is disrupted in CFS. The immune activation, the dominant
Th2 immune response, the atypical depression, the problems with orthostatic
intolerance, sleep and exercise could all have links with an altered stress
response.
The consensus regarding the HPA axis and CFS seems to be that CFS
patients mostly display a ‘mild hypoactivity’ or under-responsiveness
of the HPA as evidenced by reduced ACTH or cortisol levels. There is as yet
no indication, however, how a ‘mild’ HPA axis hypoactivity can account for
the level of debility seen in this disease. (See
Hypocortisolism, Artifact or Central Factor in CFS?)
Methods -
The authors of this
report wanted to know if a) CFS patients demonstrated indications of
increased allostatic load and b) if it was present which systems it was
present in.
The markers of
allostatic stress Maloney et. al. chose were simple; metabolism – waist/hip
ratio; cardiovascular system – blood pressure, aldosterone; immune system –
c reactive protein, albumin, IL-6; HPA axis – cortisol, DHEA-S, sympathetic
nervous system – norepinephrine, epinephrine.
Findings -
This study
found that CFS patients expressed a trend towards having higher
levels of allostatic load than the controls (P<.06). Statistically speaking
this number is not particularly strong; the lowest level of probability
deemed ‘significant’ is p<.05. It indicates there is a 6% chance that CFS
patients do not have increased allostatic load relative to the
controls. What researchers really like to see is a level of probability that
is a magnitude or more greater (i.e. p<.005).
This study found
that three components of allostatic load, waist/hip ratio, aldosterone and
urinary cortisol best differentiated the CFS patients from the controls.
Waist/hip
ratio - We knew the CFS patients were rather stout but since they were
paired with equally stout controls increased obesity could not account for
the increased waist/hip ratios seen. Instead the authors believe they
are probably due to an impaired metabolism that results in the increased
production and accumulations of fat in the midsection. This type of fat is
believed to be more biologically active than fat found elsewhere.
Increased waist/hip ratio’s increase the risk for heart disease and
diabetes. A recent study found waist/hip ratio’s were three times more
effective in predicting the risk of heart attack than the traditional
measure of obesity, body mass index.
Aldosterone
is the principle mineralocorticoid hormone produced by the adrenal cortex;
It
influences water and electrolyte (particularly sodium and potassium)
metabolism and balance. Aldosterone’major job is to facilitate potassium
exchange for sodium causing sodium reabsorption and potassium loss. It could
play a role in the low blood volume present in some CFS patients. Increased
aldosterone levels are implicated in cardiovascular disease, inflammation
and increased oxidative stress. The authors believe it could signal an
altered energy ‘set point’ of the body.
Cortisol,
a product of cortisone, is the most abundant
hormone secreted by the adrenal glands and the most potent
one.
An
antagonist to
insulin cortisol
promotes the breakdown of
lipids, and
proteins in order to
increase blood
glucose
concentrations. (Insulin promotes glucose uptake by the tissues).
A
key modulator of the immune system cortisol is also an important
anti-inflammatory agent. Reduced levels of cortisol
could, conceivably result in increased
inflammation and a predisposition for autoimmune diseases.
(See
Hypcortisolism: Artifact or Central
Factor in CFS?).
Brain Damage Causes the Increased Allostatic Load in CFS?
The researchers hypothesized that the energy ‘set point’ of brains of CFS
patients is too low. The theory that abnormal energy ‘set points’ can lead
to disease was set out in a paper called ‘The Selfish Brain: Competition for
Energy’ published in 2004. See
Selfish Brains In CFS?
.
This theory, which is quite complicated, posits that a disrupted stress
response can cause the brain to either pull too much or too little energy
(glucose) from the body. In the case of CFS, these researchers believe the
lowered cortisol levels caused by chronic stress due to infection,
psychological stress, etc. may have caused the brain to under-respond
to its own energy deficiencies. This low energy ‘set point’ would cause
decreased glucose metabolism in the brain, disrupted signaling of the main
neurotransmitter in the brain, glutamate, and increased body mass due to
increased glucose allocation and appetite. One way the brain tries to get
more glucose is to activate the feeding centers of the brain.
Evidence – Although the authors do not cite it, there is some
evidence for altered glucose metabolism in CFS. A 2003 study by Seissmeir
found impaired cerebral glucose metabolism in different parts of the
anterior cingulate region of about half the CFS patients tested. A
correlation analysis that found, however, that the reduced glucose
metabolism was associated not with fatigue or quality of life measures but
with depression and anxiety, suggested it was due to the stress from the
disease rather than an integral component of it. This is interesting given
the inability of these variables in the below study to correlate with the
levels of fatigue in CFS (see below).
The 2003 Vernon gene study that attempted to differentiate subsets in CFS
highlighted the possible importance of metabolism for some CFS patients. It
found that genes involved in glycolysis and glucose metabolism as well as
purine and pyrimidine metabolism and oxidative phosphorylation best
differentiated CFS patients with gradual onset from those with sudden onset.
The Future - Despite its relatively poor performance statistically
the CDC was impressed enough with the results that a larger study with more
extensive cardiovascular measures is planned.
We will apparently know sooner rather than latter whether our brains are
selfish or not. The authors end up the article by stating that ‘in the
near future we will determine the usefulness of this model in
determining the pathophysiology of CFS’ and suggest their results could lead
to a biomarker for CFS. If a biomarker is found it will likely be a simple
and relatively cheap one to determine as it appears it will consist of a
formula that describes levels of commonly measured substances such as
cortisol, aldosterone, etc.
Proof For and Not For The Theory; Some Symptoms in CFS are Correlated
with Allostatic Load
Goertzel, B., Pehnachin, C., Coelho, L., Maloney, E., Jones, J. and B.
Gurbaxani. 2006. Allostatic Load is associated with symptoms in chronic
fatigue syndrome patients. Pharmacogenomics 7, 485-494.
The Maloney paper found that CFS patients demonstrated a higher
allostatic load than did healthy age, sex, race and body mass index
controls. Often the next step with a finding like this is to see if it is
correlated with debility. If allostatic load is a real factor in CFS then
patients with more severe CFS should have higher allostatic loads and those
who are healthier should have lower allostatic loads.
This study used statistical tests to determine if indices of debility in
three areas (fatigue, pain, general symptom intensity/frequency using three
self-scored tests (SF-36, MFI, SI)) were correlated with measures of
allostatic load (waist/hip ratio, aldosterone, blood pressure, cortisol,
etc.). They did this by comparing the scores of CFS patients with high
levels of fatigue with low levels of fatigue, etc.
This study found allostatic load did not correlate, interestingly enough,
with fatigue but was very significantly correlated with body pain (p<.009),
and moderately correlated with physical functioning (activity levels)
(p<.02) and symptom severity (p<.05). This suggested that allostatic load
does contribute to these symptoms but not to fatigue.
Fatigue, particularly post-exertional fatigue, is the hallmark of CFS.
Pain, on the other hand, is not a hallmark but four of the eight symptoms in
the CDC definition of CFS are associated with pain, and of course, CFS bears
many similarities to Fibromyalgia, perhaps the quintessential pain disease.
Impaired physical functioning is an important part of CFS. It is unfortunate
that post-exertional fatigue is rarely assessed in these studies. These
findings suggest, however, the markers of allostatic load measured, while
important, are secondary rather than primary features of CFS.
The researchers then used a different statistical technique to determine
which measures of allostatic load contributed most to each kind of debility.
They found that high levels of c-reactive protein, a marker of inflammation,
were the best predictors of body pain; that increased levels of two
sympathetic nervous system catecholamines, norepinephrine and epinephrine
and diastolic blood pressure best predicted impaired physical functioning.
All three of these are involved in maintaining blood flows to the tissues
during exercise.
Two markers of cardiovascular functioning, systolic blood pressure and
aldosterone, best predicted high symptom severity. The authors noted that
(way back in 1993) one study found evidence of increased levels of
angiotensin converting enzyme (ACE) activity were found in CFS patients.
Like so many other promising studies no follow up studies were ever done.
They cite another paper in this volume that found altered R-R intervals.
A Spotlight on the Cardiovascular system and
Circulation – Surprisingly the only
factor included in this study that has been more or less consistently
abnormal in CFS – cortisol – did not appear to contribute greatly to the
self-reported measures of debility in these CFS patients. Instead the other
the arm of the stress response – the sympathetic nervous system (SNS) –
showed up in spades. The SNS plays a large role in circulation, the
cardiovascular system and immune regulation. Indeed almost all the factors
noted in this study are involved in one way or another in cardiovascular
functioning and circulation.
One of the key vasoconstricters in the body, norepinephrine (NE),
helps determines the amount of blood flow to the tissues. Intriguingly given
its possible role in impairing physical functioning in CFS patients it is
secreted in response to physical stress and low blood pressure.
Epinephrine (E), on the other hand, regulates heart rate and the force
of the hearts contraction, the relaxation of bronchial and intestinal
tissues and various metabolic activities. Increased SNS activity, not
surprisingly, plays a major role in heart disease. Neither NE nor E have
been well studied in CFS. Aldosterone effects blood volume and is
implicated in hypertension and heart disease. That both systolic and
diastolic blood pressure showed up in this analysis further suggests a
cardiovascular component to CFS. Raised c-reactive protein levels are
commonly found in inflammatory diseases and are considered a risk factor for
heart disease.
More findings suggestive of impaired circulation have recently emerged.
Natelson just published a study finding reduced cortical blood flows in CFS.
Some researchers believe that altered SNS functioning in the muscles of FMS
patients contributes to the pain found there. Given all this interesting
data, one looks forward with increased anticipation to the big Hurwitz study
on blood volume in CFS (that began in 2000 - a plague on all 6 year
studies!) and the Peckerman study on systolic functioning that was supposed
to have been published last year.
Not surprisingly, given the target placed on cardiovascular functioning
in CFS by these findings, the authors state they will look more closely at
the cardiovascular system in future studies.
CONCLUSIONS
Significant or Not? –
It is unclear how significant these findings are. Yes, there are
indications of increased allostatic load in CFS. Yes, they occur in two
systems of interest in CFS, the cardiovascular and metabolic systems. While
CFS patients do exhibit several characteristics one would expect to show up
in a disease characterized by a disturbed stress response, namely low
cortisol levels and signs of immune activation, the cortisol levels in CFS
are only ‘mildly’ low (and not infrequently normal), and the results of
cytokine studies have been inconsistent as well. We haven’t seen thus far a
level of aberration that can in any way account for the debility seen in
CFS. Of course these allostatic load studies are preliminary; they focused
on broad measures of allostatic load spread across several systems. The next
studies that focus more on specific systems should be the really important
ones; they should begin to tell us whether these studies will be the
beginnings of something really significant for CFS or whether they are
merely the signs of a disease that is stressful in so many ways.
The Chicken or the Egg? – Given the
difficulty in finding a central pathogen in CFS researchers have for many
years tried to understand how a triggering event such as an infection could
lead to such a long term chronic illness. An infection caused aberration in
the stress response could provide a satisfactory model for many CFS
patients.
A major unanswered question, however, is whether the stresses associated
with having a chronic disease such as CFS causes the increased allostatic
loads seen or if CFS is the result of an aberrant allostatic stress
response? Does one try to remove the stressor (i.e. infection, toxin,
psychological trauma, etc.?) or does one try to rebalance the stress
response system? If, for instance, a chronic, albeit still undiagnosed
infection is at the root of ones CFS then adjusting the stress response
could prove detrimental (See
Hypocortisolism in CFS; Artifact or Central Factor?).
If, on the other hand, the pathogen is simply an incidental trigger that
caused the stress response to go haywire, then there is no sense in dealing
the pathogen as it is likely long gone.
This second scenario is complicated by the possibility that an altered
stress response could, through its deregulation of the immune response,
allow the introduction of opportunistic pathogens that cause further
problems; i.e. the pathogen one treats in CFS may not be the one responsible
for the initial pathology. A similar scenario could be envisioned regarding
the cardiovascular system. It is intriguing that researchers and physicians
such as Dr. Cheney have posited almost from the beginning a scenario
involving an initial and long term dysregulation involving the hypothalamus,
a key player in the stress response.
A third scenario involves not an initial deregulation of the stress
response but a slow decline over time due to the stresses accompanying CFS.
There is some evidence for this: a prospective study found no HPA axis
changes in EBV patients that still had increased fatigue six months after
infection.
A Laymen’s Ravings- Metabolic syndrome and CFS
– Are these researchers suggesting CFS patients have metabolic
syndrome? People with metabolic syndrome have increased waist/hip ratios,
elevated triglycerides, reduced HDL cholesterol, increased blood pressure,
and increased blood glucose levels, increased sympathetic nervous system
activity, low levels of growth hormone, high uric acid levels, increased
leptin and lactic acid levels, high c-reactive protein, electrolyte
imbalances, increased oxidative stress and increased fibrinogen, IL-6 and
TNF-a. Most people with metabolic syndrome are obese but not all are – they
can have normal weight as well. What they do display are increased levels of
body fat, particularly around the midsection.
How do CFS patients compare to metabolic syndrome patients? Given the
heterogeneous findings for many of these tests in CFS its hard to
definitively say. Some CFS patients in some studies have exhibited
increased waist/hip ratios, increased sympathetic nervous system activity,
low growth hormone levels, high lactic acid levels, higher c-reactive
protein levels, altered electrolyte levels, increased fibrinogen, IL-6 and
TNF-a. Other studies have shown differently with regard to SNS activity,
growth hormone, lactic acid, fibrinogen, Il-6 and TNF-a. Dr. Cheney has
stated that his patients have low, not high, uric acid levels. Virtually all
studies that I am aware of have indicated increased oxidative stress in CFS.
At this point there do appear to be some broad similarities between the two
syndromes.
One scenario for metabolic syndrome suggests it begins with the increased
production of biologically active fat which triggers the production of the
pro-inflammatory cytokines TNF-a and IL-6 which arethe major players in the
increased inflammation, oxidative stress and insulin resistance seen. The
same dysfunction of metabolism that spurs growth of fat cells in the
midsection also over time contributes to poor health, degenerative
conditions and premature death.
One could hardly suggest that CFS is metabolic syndrome; far more
people have metabolic syndrome - 1/5th of the adults in the US –
than have CFS. But could having CFS increase one’s risk for metabolic
syndrome?
*Update - this raving at least had some basis. Dr. Maloney
reported at the 2007 IACFS conference that about a third of CFS patients met
the criteria for metabolic syndrome. Her report is summarized in Part I of
the Overview of the Professional Conference
(click here)
To
Pharmacogenomics Introduction /
Pharma II: Gene Expression /Pharma
III Gene Polymorphisms/
Pharma IV :
Subsets
_________________________
McEwen, B.2000. Allostasis, allostatic load, and the aging nervous
system: role of excitatory amino acids and excitotoxity. Neurochemical
Research 25, 1219-31.
McEwen B. 2004. Protection and damage from acute and chronic stress.
Allostasis and allostatic overload and relevance to the pathophysiology of
psychiatric disorders. Annals of NY Acad. Sci 1032: 1-7.